161 related articles for article (PubMed ID: 22489023)
1. Differential positioning and close spatial proximity of translocation-prone genes in nonmalignant B-cells from multiple myeloma patients.
Martin LD; Harizanova J; Zhu G; Righolt CH; Belch AR; Mai S; Pilarski LM
Genes Chromosomes Cancer; 2012 Aug; 51(8):727-42. PubMed ID: 22489023
[TBL] [Abstract][Full Text] [Related]
2. Differential nuclear organization of translocation-prone genes in nonmalignant B cells from patients with t(14;16) as compared with t(4;14) or t(11;14) myeloma.
Martin LD; Harizanova J; Righolt CH; Zhu G; Mai S; Belch AR; Pilarski LM
Genes Chromosomes Cancer; 2013 Jun; 52(6):523-37. PubMed ID: 23460268
[TBL] [Abstract][Full Text] [Related]
3. FGFR3 preferentially colocalizes with IGH in the interphase nucleus of multiple myeloma patient B-cells when FGFR3 is located outside of CT4.
Martin LD; Harizanova J; Mai S; Belch AR; Pilarski LM
Genes Chromosomes Cancer; 2016 Dec; 55(12):962-974. PubMed ID: 27509849
[TBL] [Abstract][Full Text] [Related]
4. Promiscuity of translocation partners in multiple myeloma.
Martin LD; Belch AR; Pilarski LM
J Cell Biochem; 2010 Apr; 109(6):1085-94. PubMed ID: 20127714
[TBL] [Abstract][Full Text] [Related]
5. JAK2V617F-positive essential thrombocythemia and multiple myeloma with IGH/CCND1 gene translocation coexist, but originate from separate clones.
Kuroda J; Matsumoto Y; Tanaka R; Kurita K; Kobayashi T; Shimizu D; Kimura S; Ashihara E; Horiike S; Shimazaki C; Taniwaki M
Acta Haematol; 2008; 120(3):177-81. PubMed ID: 19129688
[TBL] [Abstract][Full Text] [Related]
6. A potential role for centrosomal deregulation within IgH translocation-positive myeloma.
Maxwell CA; Pilarski LM
Med Hypotheses; 2005; 65(5):915-21. PubMed ID: 16023302
[TBL] [Abstract][Full Text] [Related]
7. Various patterns of IgH deletion identified by FISH using combined IgH and IgH/CCND1 probes in multiple myeloma and chronic lymphocytic leukemia.
Hwang Y; Lee JY; Mun YC; Seong CM; Chung WS; Huh J
Int J Lab Hematol; 2011 Jun; 33(3):299-304. PubMed ID: 21272268
[TBL] [Abstract][Full Text] [Related]
8. Quick detection of overexpressed genes caused by myeloma-specific chromosomal translocations using multiplex RT-PCR.
Htwe SS; Maeda M; Matsumoto R; Sakamoto N; Murakami S; Yamamoto S; Katoh M; Kumagai N; Hayashi H; Nishimura Y; Ohkura M; Wada H; Taniwaki M; Sugihara T; Otsuki T
Int J Mol Med; 2011 Jun; 27(6):789-94. PubMed ID: 21399865
[TBL] [Abstract][Full Text] [Related]
9. Spatial proximity of translocation-prone gene loci in human lymphomas.
Roix JJ; McQueen PG; Munson PJ; Parada LA; Misteli T
Nat Genet; 2003 Jul; 34(3):287-91. PubMed ID: 12808455
[TBL] [Abstract][Full Text] [Related]
10. FGFR3 is expressed and is important for survival in INA-6, a human myeloma cell line without a t(4;14).
Våtsveen TK; Brenne AT; Dai HY; Waage A; Sundan A; Børset M
Eur J Haematol; 2009 Nov; 83(5):471-6. PubMed ID: 19594619
[TBL] [Abstract][Full Text] [Related]
11. Molecular classification of multiple myeloma: a distinct transcriptional profile characterizes patients expressing CCND1 and negative for 14q32 translocations.
Agnelli L; Bicciato S; Mattioli M; Fabris S; Intini D; Verdelli D; Baldini L; Morabito F; Callea V; Lombardi L; Neri A
J Clin Oncol; 2005 Oct; 23(29):7296-306. PubMed ID: 16129847
[TBL] [Abstract][Full Text] [Related]
12. Nuclear localization of translocation partners in differentiating B-cells.
Sklyar IV; Pichugin AM; Razin SV; Vassetzky ES; Iarovaia OV
Dokl Biochem Biophys; 2015; 464():312-4. PubMed ID: 26518556
[TBL] [Abstract][Full Text] [Related]
13. Correlation between losses of IGH or its segments and deletions of 13q14 in t(11;14) (q13;q32) multiple myeloma.
Trakhtenbrot L; Hardan I; Koren-Michowitz M; Oren S; Yshoev G; Rechavi G; Nagler A; Amariglio N
Genes Chromosomes Cancer; 2010 Jan; 49(1):17-27. PubMed ID: 19787791
[TBL] [Abstract][Full Text] [Related]
14. The biology of multiple myeloma.
Drach J; Kaufmann H; Urbauer E; Schreiber S; Ackermann J; Huber H
J Cancer Res Clin Oncol; 2000 Aug; 126(8):441-7. PubMed ID: 10961386
[TBL] [Abstract][Full Text] [Related]
15. A myeloma translocation-like model associating CCND1 with the immunoglobulin heavy-chain locus 3' enhancers does not promote by itself B-cell malignancies.
Fiancette R; Amin R; Truffinet V; Vincent-Fabert C; Cogné N; Cogné M; Denizot Y
Leuk Res; 2010 Aug; 34(8):1043-51. PubMed ID: 20018375
[TBL] [Abstract][Full Text] [Related]
16. In multiple myeloma, circulating hyperdiploid B cells have clonotypic immunoglobulin heavy chain rearrangements and may mediate spread of disease.
Pilarski LM; Giannakopoulos NV; Szczepek AJ; Masellis AM; Mant MJ; Belch AR
Clin Cancer Res; 2000 Feb; 6(2):585-96. PubMed ID: 10690543
[TBL] [Abstract][Full Text] [Related]
17. FGFR3 amplification in the absence of IGH@-FGFR3 fusion t(4;14) in myeloma.
Quintero-Rivera F; El-Sabbagh Badr R; Rao PN
Cancer Genet Cytogenet; 2009 Nov; 195(1):92-3. PubMed ID: 19837276
[No Abstract] [Full Text] [Related]
18. Distinct Patterns of Colocalization of the CCND1 and CMYC Genes With Their Potential Translocation Partner IGH at Successive Stages of B-Cell Differentiation.
Sklyar I; Iarovaia OV; Gavrilov AA; Pichugin A; Germini D; Tsfasman T; Caron G; Fest T; Lipinski M; Razin SV; Vassetzky YS
J Cell Biochem; 2016 Jul; 117(7):1506-10. PubMed ID: 26873538
[TBL] [Abstract][Full Text] [Related]
19. Frequency and distribution of trisomy 11 in multiple myeloma patients: relation with overexpression of CCND1 and t(11;14).
Guglielmelli T; Giugliano E; Cappia S; Papotti M; Saglio G
Cancer Genet Cytogenet; 2007 Feb; 173(1):51-6. PubMed ID: 17284370
[TBL] [Abstract][Full Text] [Related]
20. Early genetic events provide the basis for a clinical classification of multiple myeloma.
Kuehl WM; Bergsagel PL
Hematology Am Soc Hematol Educ Program; 2005; ():346-52. PubMed ID: 16304402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
